全球特殊醫藥品的聯盟條件與契約 (2019～2024年)

本報告提供了有關公司為何以及在什麼條件下簽訂專業製藥合作協議的詳細資訊和分析。這些協議往往是多方面的，從聯合研發開始，一直到成果的商業化。

本報告提供了自 2019 年以來生命科學領域宣布的 1,066 項特種製藥協議的詳細資訊。

本報告對特種藥品領域的合約趨勢、主要公司、主要合約金額和合約財務進行了全面回顧，並研究了每家公司如何、為何以及在什麼條件下簽訂特種藥品合作協議，您可以了解什麼。

本報告從財務角度評估了特種藥品交易的期限和價值，並提供了交易總額、預付款、里程碑和特許權使用費率等信息，以幫助讀者了解交易的財務價值。比較。

本報告的中間部分研究了專業製藥聯盟的主要交易者。報告了特種藥品領域主要交易的交易價值和最活躍的交易撮合者，讓讀者了解哪些公司在這個充滿活力的交易市場中取得了成功。

對於特殊藥品的實際交易，我們提供交易方揭露的線上交易記錄，按公司名稱（A-Z）、開發階段、交易類型、特定治療標靶和技術類型列於報告末尾。 。報告中的每個交易記錄都透過網路連結連結到交易的線上版本。

此外，如果有的話，我們會記錄公司及其附屬公司向美國證券交易委員會提交的合約文件。雖然許多公司希望了解其付款條件的詳細信息，但在付款方式方面，細節才是王道。

本報告還包括一些圖表，顯示 2019 年以來專業製藥聯盟和交易的趨勢和活動。

總之，我們為未來的交易者提供了有關專業藥品研發和商業化合作所需的一切資訊。

主要優點

該報告為讀者提供了以下主要好處：

• 有關特種藥品合約趨勢的詳細資訊（自 2019 年起）
• 取得交易金額、預付款、里程碑和版稅率數據
• 與主要生物製藥公司簽署的特種藥品實際協議：查看詳細信息
• 確定特種藥品領域最活躍的交易撮合者（2019 年及以後）
• 公司過去同意的主要合約條件的說明
• 進行盡職調查：評估向合作夥伴公司提出的合約條款的適當性

調查範圍

• 本報告旨在讓讀者深入了解和了解全球領先的特種藥品公司所進行的交易的趨勢和結構。

特種藥物的合作條件與合約細節：

• 生醫產業專科藥品貿易趨勢（2019年起）
• 取得交易金額、預付款、里程碑和版稅率數據
• 取得特種藥物的合約文件
• 特種藥品主要總交易額和k需求（2019年以來）
• 專業藥品領域最活躍的交易撮合者（2019 年起）

此報告列出了可用合約的以下資訊：

• 公司名稱（A-Z）
• 總交易金額
• 合約簽訂時的開發階段
• 合約組成部分的類型
• 具體治療標靶
• 技術類型
• 每筆交易的標題都透過網路連結連結到交易記錄的線上版本以及合約文件（如果有），從而可以輕鬆按需存取每份合約文件。

透過分析實際合同，可以評估：

• 授予或選擇的具體權利是什麼？
• 合約實際上賦予了合作夥伴公司什麼？
• 授予哪些類型的專有權？
• 合約的付款結構是怎樣的？
• 如何審核銷售和付款？
• 條款和條件是什麼？
• 合約的主要條款是如何定義的？
• 智慧財產權的處理和所有權如何？
• 誰負責商業化？
• 誰負責開發、供應和製造？
• 如何管理保密和發布？
• 如何解決爭議？
• 什麼情況下可以取消合約？
• 如果所有者發生變化會怎樣？
• 已就何種類型的分授權或分包條款達成協議？
• 公司主張哪些樣板條款？
• 根據合作夥伴關係或交易的類型，哪些樣板條款看起來有所不同？
• 公司對契約法主張哪一個管轄權？

目錄

摘要整理

第1章 簡介

第2章 特殊醫藥品的交易趨勢

• 簡介
• 特殊醫藥品的長期性的聯盟趨勢
• 在特殊醫藥品中最活躍的交易商
• 特殊醫藥品的聯盟趨勢:各交易類型
• 特殊醫藥品的聯盟趨勢:各治療領域
• 特殊醫藥品的聯盟趨勢:各技術種類
• 特殊醫藥品的聯盟條件
  • 特殊醫藥品的聯盟的交易總額
  • 特殊醫藥品的交易的預付款金
  • 特殊醫藥品的交易的里程金
  • 特殊醫藥品的特許權率

第3章 特殊醫藥品的主要交易

• 簡介
• 特殊醫藥品的主要交易:交易額

第4章 特殊醫藥品的最活躍的交易商

• 簡介
• 特殊醫藥品的最活躍的交易商
• 特殊醫藥品的最活躍的聯盟企業:簡介

第5章 特殊醫藥品的契約交易一覽

• 簡介
• 特殊醫藥品的契約交易一覽

第6章 特殊醫藥品的交易趨勢:各技術種類

附錄

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 report provides a detailed understanding and analysis of how and why companies enter specialty pharmaceutical partnering deals.

This report provides details of 1,066 specialty pharmaceutical agreements announced in the life sciences since 2019.

The report takes the reader through a comprehensive review specialty pharmaceutical deal trends, key players, top deal values, as well as deal financials, allowing the understanding of how, why and under what terms, companies are entering specialty pharmaceutical partnering deals.

The report presents financial deal term values for specialty pharmaceutical deals, listing by headline value, upfront payments, milestone payments and royalties, enabling readers to analyse and benchmark the financial value of deals.

The middle section of the report explores the leading dealmakers in the specialty pharmaceutical partnering field; both the leading deal values and most active specialty pharmaceutical dealmaker companies are reported allowing the reader to see who is succeeding in this dynamic dealmaking market.

Online deal records of actual specialty pharmaceutical deals, as disclosed by the deal parties, are included towards the end of the report in a directory format - by company A-Z, stage of development, deal type, therapy focus, and technology type - that is easy to reference. Each deal record in the report links via hyperlink to an online version of the deal.

In addition, where available, records include contract documents as submitted to the Securities Exchange Commission by companies and their partners. Whilst many companies will be seeking details of the payment clauses, the devil is in the detail in terms of how payments are triggered - contract documents provide this insight where press releases and databases do not.

The initial chapters of this report provide an orientation of specialty pharmaceutical dealmaking. Chapter 1 provides an introduction to the report, whilst chapter 2 provides an overview of the trends in specialty pharmaceutical dealmaking since 2019, including details of headline, upfront, milestone and royalty terms.

Chapter 3 provides a review of the leading specialty pharmaceutical deals since 2019. Deals are listed by headline value. Where the deal has an agreement contract published at the SEC a link provides online access to the contract.

Chapter 4 provides a comprehensive listing of the top 25 most active companies in specialty pharmaceutical dealmaking with a brief summary followed by a comprehensive listing of specialty pharmaceutical deals announded by that company, as well as contract documents, where available.

Chapter 5 provides a comprehensive and detailed review of specialty pharmaceutical partnering deals signed and announced since January 2019, where a contract document is available in the public domain. Each deal title links via hyperlink to an online version of the deal record and contract document, providing easy access to each contract document on demand.

Chapter 6 provides a comprehensive and detailed review of specialty pharmaceutical partnering deals signed and announced since January 2019. The chapter is organized by specific technology type. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

A comprehensive series of appendices is provided organized by specialty pharmaceutical partnering company A-Z, stage of development, deal type, and therapy focus. Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each deal on demand.

The report also includes numerous tables and figures that illustrate the trends and activities in specialty pharmaceutical partnering and dealmaking since 2019.

In conclusion, this report provides everything a prospective dealmaker needs to know about partnering in the research, development and commercialization of specialty pharmaceutical technologies and products.

Key benefits

Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 provides the reader with the following key benefits:

• In-depth understanding of specialty pharmaceutical deal trends since 2019
• Access to headline, upfront, milestone and royalty data
• Detailed access to actual specialty pharmaceutical contracts entered into by leading biopharma companies
• Identify most active specialty pharmaceutical dealmakers since 2019
• Understand the key deal terms companies have agreed in previous deals
• Undertake due diligence to assess suitability of your proposed deal terms for partner companies

Report scope

• Global Specialty Pharmaceutical Partnering Terms and Agreements 2019-2024 is intended to provide the reader with an in-depth understanding and access to specialty pharmaceutical trends and structure of deals entered into by leading companies worldwide.

Specialty Pharmaceutical Partnering Terms and Agreements includes:

• Trends in specialty pharmaceutical dealmaking in the biopharma industry since 2019
• Access to headline, upfront, milestone and royalty data
• Access to specialty pharmaceutical contract documents
• Leading specialty pharmaceutical deals by value since 2019
• Most active specialty pharmaceutical dealmakers since 2019

In Global Specialty Pharmaceutical Partnering Terms and Agreements, the available deals are listed by:

• Company A-Z
• Headline value
• Stage of development at signing
• Deal component type
• Specific therapy target
• Technology type
• Each deal title links via hyperlink to an online version of the deal record and where available, the contract document, providing easy access to each contract document on demand.

Analyzing actual contract agreements allows assessment of the following:

• What are the precise rights granted or optioned?
• What is actually granted by the agreement to the partner company?
• What exclusivity is granted?
• What is the payment structure for the deal?
• How are sales and payments audited?
• What is the deal term?
• How are the key terms of the agreement defined?
• How are IPRs handled and owned?
• Who is responsible for commercialization?
• Who is responsible for development, supply, and manufacture?
• How is confidentiality and publication managed?
• How are disputes to be resolved?
• Under what conditions can the deal be terminated?
• What happens when there is a change of ownership?
• What sublicensing and subcontracting provisions have been agreed?
• Which boilerplate clauses does the company insist upon?
• Which boilerplate clauses appear to differ from partner to partner or deal type to deal type?
• Which jurisdiction does the company insist upon for agreement law?

Table of Contents

Executive Summary

Chapter 1 - Introduction

Chapter 2 - Trends in specialty pharmaceutical dealmaking

• 2.1. Introduction
• 2.2. Specialty pharmaceutical partnering over the years
• 2.3. Most active specialty pharmaceutical dealmakers
• 2.4. Specialty pharmaceutical partnering by deal type
• 2.5. Specialty pharmaceutical partnering by therapy area
• 2.6. Specialty pharmaceutical partnering by technology type
• 2.7. Deal terms for specialty pharmaceutical partnering
  • 2.7.1 Specialty pharmaceutical partnering headline values
  • 2.7.2 Specialty pharmaceutical deal upfront payments
  • 2.7.3 Specialty pharmaceutical deal milestone payments
  • 2.7.4 Specialty pharmaceutical royalty rates

Chapter 3 - Leading specialty pharmaceutical deals

• 3.1. Introduction
• 3.2. Top specialty pharmaceutical deals by value

Chapter 4 - Most active specialty pharmaceutical dealmakers

• 4.1. Introduction
• 4.2. Most active specialty pharmaceutical dealmakers
• 4.3. Most active specialty pharmaceutical partnering company profiles

Chapter 5 - Specialty pharmaceutical contracts dealmaking directory

• 5.1. Introduction
• 5.2. Specialty pharmaceutical contracts dealmaking directory

Chapter 6 - Specialty pharmaceutical dealmaking by technology type

Appendices

• Appendix 1 - Specialty pharmaceutical deals by company A-Z
• Appendix 2 - Specialty pharmaceutical deals by stage of development
• Appendix 3 - Specialty pharmaceutical deals by deal type
• Appendix 4 - Specialty pharmaceutical deals by therapy area
• Appendix 5 - Deal type definitions
• Appendix 6 - Further reading
• About Biopharma Research
• Current Partnering
• Current Agreements
• Recent report titles from Current Partnering

Table of figures

• Figure 1: Specialty pharmaceutical partnering since 2019
• Figure 2: Active specialty pharmaceutical dealmaking activity 2019-2024
• Figure 3: Specialty pharmaceutical partnering by deal type since 2019
• Figure 4: Specialty pharmaceutical partnering by disease type since 2019
• Figure 5: Specialty pharmaceutical partnering by technology type since 2019
• Figure 6: Specialty pharmaceutical deals with a headline value
• Figure 7: Specialty pharmaceutical deals with an upfront value
• Figure 8: Specialty pharmaceutical deals with a milestone value
• Figure 9: Specialty pharmaceutical deals with a royalty rate value
• Figure 10: Top specialty pharmaceutical deals by value since 2019
• Figure 11: Most active specialty pharmaceutical dealmakers 2019-2024